Open AccessComparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
Author(s) -
Jorge Blando,
Anu Sharma,
Maria G. Higa,
Hao Zhao,
Luis M. Vence,
Shalini S. Yadav,
Jiseong Kim,
Alejandro Martínez Sepúlveda,
Michael Sharp,
Anirban Maitra,
Jennifer A. Wargo,
Michael T. Tetzlaff,
Russell Broaddus,
Matthew H. G. Katz,
Gauri R. Varadhachary,
Michael J. Overman,
Huamin Wang,
Cassian Yee,
Chantale Bernatchez,
Christine A. Iacobuzio–Donahue,
Sreyashi Basu,
James P. Allison,
Padmanee Sharma
Publication year - 2019
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1811067116
Subject(s) - pancreatic cancer , tumor microenvironment , immune system , cancer research , stromal cell , medicine , melanoma , immunotherapy , pancreatic tumor , cd68 , tumor infiltrating lymphocytes , immune checkpoint , cd8 , cancer , immunology , immunohistochemistry
Significance The study demonstrates that V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint that is preferentially expressed at higher levels in pancreatic cancer. The study gives a detailed analysis of immune infiltration in primary and metastatic pancreatic tumors compared with melanoma, which differs in its tumor/stromal distribution. Our data indicate that human pancreatic tumors express CD68+ macrophages and highlight the inhibitory checkpoint molecule VISTA as a potential immunotherapeutic target in pancreatic cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom